Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016, 42540-42544 [2015-17561]
Download as PDF
42540
Federal Register / Vol. 80, No. 137 / Friday, July 17, 2015 / Notices
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–420N]
Proposed Aggregate Production
Quotas for Schedule I and II Controlled
Substances and Assessment of
Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2016
Drug Enforcement
Administration, Department of Justice.
ACTION: Notice with request for
comments.
AGENCY:
The Drug Enforcement
Administration proposes to establish the
2016 aggregate production quotas for
controlled substances in schedules I and
II of the Controlled Substances Act and
assessment of annual needs for the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
SUMMARY:
Interested persons may file
written comments on or objections to
this notice in accordance with 21 CFR
1303.11(c) and 1315.11(d). Electronic
comments must be submitted, and
written comments must be postmarked,
on or before August 17, 2015.
Commenters should be aware that the
electronic Federal Docket Management
System will not accept comments after
11:59 p.m. Eastern Time on the last day
of the comment period.
The Administrator may hold a public
hearing on one or more issues raised by
the comments received in response to
this notice. In the event the
Administrator decides in his sole
discretion to hold such a hearing, the
Administrator will publish a notice of
any such hearing in the Federal
Register. After consideration of any
comments and after a hearing, if one is
held, the Administrator will publish in
the Federal Register a final order
establishing the 2016 aggregate
production quotas for schedule I and II
controlled substances, and an
assessment of annual needs for the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
DATES:
To ensure proper handling
of comments, please reference ‘‘Docket
No. DEA–420N’’ on all correspondence,
including any attachments. The Drug
Enforcement Administration encourages
that all comments be submitted
electronically through the Federal
eRulemaking Portal which provides the
ability to type short comments directly
into the comment field on the Web page
or attach a file for lengthier comments.
srobinson on DSK5SPTVN1PROD with NOTICES
ADDRESSES:
VerDate Sep<11>2014
20:59 Jul 16, 2015
Jkt 235001
Please go to https://www.regulations.gov
and follow the online instructions at
that site for submitting comments. Upon
completion of your submission you will
receive a Comment Tracking Number for
your comment. Please be aware that
submitted comments are not
instantaneously available for public
view on Regulations.gov. If you have
received a Comment Tracking Number,
your comment has been successfully
submitted and there is no need to
resubmit the same comment. Paper
comments that duplicate electronic
submissions are not necessary and are
discouraged. Should you wish to mail a
paper comment in lieu of an electronic
comment, it should be sent via regular
or express mail to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODL, 8701
Morrissette Drive, Springfield, Virginia
22152.
FOR FURTHER INFORMATION CONTACT: John
R. Scherbenske, Office of Diversion
Control, Drug Enforcement
Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia
22152, Telephone: (202) 598–6812.
SUPPLEMENTARY INFORMATION:
Posting of Public Comments
Please note that all comments
received in response to this docket are
considered part of the public record.
They will, unless reasonable cause is
given, be made available for public
inspection online at https://
www.regulations.gov. Such information
includes personal identifying
information (such as your name,
address, etc.) voluntarily submitted by
the commenter. The Freedom of
Information Act applies to all comments
received. If you want to submit personal
identifying information (such as your
name, address, etc.) as part of your
comment, but do not want it to be
posted online or made available in the
public docket, you must include the
phrase ‘‘PERSONAL IDENTIFYING
INFORMATION’’ in the first paragraph
of your comment. You must also place
all the personal identifying information
you do not want publicly available in
the first paragraph of your comment and
identify what information you want
redacted.
If you want to submit confidential
business information as part of your
comment, but do not want it to be made
publicly available, you must include the
phrase ‘‘CONFIDENTIAL BUSINESS
INFORMATION’’ in the first paragraph
of your comment. You must also
prominently identify confidential
business information to be redacted
within the comment.
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
Comments containing personal
identifying information or confidential
business information identified and
located as directed above will generally
be made available in redacted form. If a
comment contains so much personal
identifying information or confidential
business information that it cannot be
effectively redacted, all or part of that
comment may not be made publicly
available. Comments posted to https://
www.regulations.gov may include any
personal identifying information (such
as name, address, and phone number)
included in the text of your electronic
submission that is not identified as
directed above as personal.
An electronic copy of this document
is available at https://
www.regulations.gov for easy reference.
Legal Authority
The Drug Enforcement
Administration (DEA) implements and
enforces titles II and III of the
Comprehensive Drug Abuse Prevention
and Control Act of 1970, as amended. 21
U.S.C. 801–971. Titles II and III are
referred to as the ‘‘Controlled
Substances Act’’ and the ‘‘Controlled
Substances Import and Export Act,’’
respectively, and are collectively
referred to as the ‘‘Controlled
Substances Act’’ or the ‘‘CSA’’ for the
purpose of this action. The DEA
publishes the implementing regulations
for these statutes in title 21 of the Code
of Federal Regulations (CFR), chapter II.
The CSA and its implementing
regulations are designed to prevent,
detect, and eliminate the diversion of
controlled substances and listed
chemicals into the illicit market while
ensuring an adequate supply is available
for the legitimate medical, scientific,
research, and industrial needs of the
United States. Controlled substances
have the potential for abuse and
dependence and are controlled to
protect the public health and safety.
Section 306 of the CSA (21 U.S.C.
826) requires the Attorney General to
establish aggregate production quotas
for each basic class of controlled
substance listed in schedules I and II
and to establish the assessment of
annual needs for the list I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine. The Attorney
General has delegated this function to
the Administrator of the DEA pursuant
to 28 CFR 0.100.
Analysis for Proposed 2016 Aggregate
Production Quotas and Assessment of
Annual Needs
The proposed year 2016 aggregate
production quotas and assessment of
annual needs represent those quantities
E:\FR\FM\17JYN1.SGM
17JYN1
Federal Register / Vol. 80, No. 137 / Friday, July 17, 2015 / Notices
of schedule I and II controlled
substances, and the list I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine, to be
manufactured in the United States in
2016 to provide for the estimated
medical, scientific, research, and
industrial needs of the United States,
lawful export requirements, and the
establishment and maintenance of
reserve stocks. These proposals include
estimated imports of ephedrine,
pseudoephedrine, and
phenylpropanolamine but do not
include estimated imports of controlled
substances for use in industrial
processes.
In determining the proposed 2016
aggregate production quotas and
assessment of annual needs, the
Administrator has taken into account
the criteria that is required to be
considered in accordance with 21 U.S.C.
826(a), 21 CFR 1303.11 (aggregate
production quotas for controlled
substances), and 21 CFR 1315.11
(assessment of annual needs for
ephedrine, pseudoephedrine, and
phenylpropanolamine). The
Administrator estimates the aggregate
production quotas and assessment of
annual needs for 2016 by considering
the following factors: (1) Total net
disposal of each class or chemical by all
manufacturers and chemical importers
during the current and two preceding
years; (2) trends in the national rate of
net disposal of the class or chemical; (3)
total actual (or estimated) inventories of
the class or chemical and of all
substances manufactured from the class
or chemical, and trends in inventory
accumulation; (4) projected demand for
each class or chemical as indicated by
procurement and chemical import
quotas requested in accordance with 21
CFR 1303.12, 1315.32, and 1315.34; and
(5) other factors affecting the medical,
scientific, research, and industrial needs
of the United States, lawful export
requirements, and reserve stocks, as the
Administrator finds relevant.
Other factors the Administrator
considered in calculating the aggregate
production quotas, but not the
assessment of annual needs, include
product development requirements of
both bulk and finished dosage form
manufacturers, and other pertinent
information. In determining the
proposed 2016 assessment of annual
needs, the DEA used the calculation
methodology previously described in
the 2010 and 2011 assessments of
annual needs (74 FR 60294, Nov. 20,
2009, and 75 FR 79407, Dec. 20, 2010,
respectively).
The Administrator also specifically
considered that inventory allowances
granted to individual manufacturers
may not always result in the availability
of sufficient quantities to maintain an
adequate reserve stock pursuant to 21
U.S.C. 826(a), as intended. See 21 CFR
1303.24. This would be of concern if a
natural disaster or other unforeseen
event resulted in substantial disruption
to the amount of controlled substances
42541
available to provide for legitimate
public need. As such, the Administrator
proposes to include in all schedule II
aggregate production quotas, and certain
schedule I aggregate production quotas
(difenoxin, gamma-hydroxybutyric acid,
and tetrahydrocannabinols), an
additional 25% of the estimated
medical, scientific, and research needs
as part of the amount necessary to
ensure the establishment and
maintenance of reserve stocks. The
proposed aggregate production quotas
reflect these included amounts. This
action will not affect the ability of
manufacturers to maintain inventory
allowances as specified by regulation.
The Administrator expects that
maintaining this reserve in certain
established aggregate production quotas
will mitigate adverse public effects if an
unforeseen event results in substantial
disruption to the amount of controlled
substances available to provide for
legitimate public need, as determined
by the Administrator. The
Administrator does not anticipate
utilizing the reserve in the absence of
these circumstances.
The Administrator, therefore,
proposes to establish the 2016 aggregate
production quotas for the following
basic classes of schedule I and II
controlled substances and assessment of
annual needs for the list I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine, expressed in
grams of anhydrous acid or base, as
follows:
Proposed 2016
quotas
(g)
Basic class
srobinson on DSK5SPTVN1PROD with NOTICES
Schedule I
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) .............................................................................
[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) ...............................................................
[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ-2201) ................................................................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone) .................................................................................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone) .............................................................................................
1-(1-Phenylcyclohexyl)pyrrolidine ..................................................................................................................................................
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ......................................................................................................................
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) .....................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine .............................................................................................................................................
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) .........................................................................................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073) ......................................................................................................................................
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8) .....................................................................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019) .....................................................................................................................................
1-Methyl-4-phenyl-4-propionoxypiperidine .....................................................................................................................................
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) ................................................................................................................
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) ......................................................................................................................
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) ..................................................................................................................
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) ......................................................................................................................
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) .....................................................................................................................
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) ..............................................................................................................
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) .................................................................................................................
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) ................................................................................................................
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) .....................................................................................................................
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) ..................................................................................................................
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) ....................................................................................................................
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) .................................................................................................................................
VerDate Sep<11>2014
20:59 Jul 16, 2015
Jkt 235001
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
E:\FR\FM\17JYN1.SGM
17JYN1
25
25
15
25
25
10
45
45
15
45
45
45
45
2
45
45
45
45
45
45
45
30
30
30
30
30
42542
Federal Register / Vol. 80, No. 137 / Friday, July 17, 2015 / Notices
Proposed 2016
quotas
(g)
srobinson on DSK5SPTVN1PROD with NOTICES
Basic class
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) ..................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) ..................................................................................................................
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) ..................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) ........................................................................................................................
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) ............................
2-(Methylamino)-1-phenylpentan-1-one (pentedrone) ...................................................................................................................
2,5-Dimethoxy-4-ethylamphetamine (DOET) ................................................................................................................................
2,5-Dimethoxy-4-n-propylthiophenethylamine ...............................................................................................................................
2,5-Dimethoxyamphetamine ..........................................................................................................................................................
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) ..........................................................................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) ....................................................................................................
3,4,5-Trimethoxyamphetamine ......................................................................................................................................................
3,4-Methylenedioxyamphetamine (MDA) ......................................................................................................................................
3,4-Methylenedioxymethamphetamine (MDMA) ...........................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .......................................................................................................................
3,4-Methylenedioxy-N-methylcathinone (methylone) ....................................................................................................................
3,4-Methylenedioxypyrovalerone (MDPV) .....................................................................................................................................
3-Fluoro-N-methylcathinone (3-FMC) ............................................................................................................................................
3-Methylfentanyl .............................................................................................................................................................................
3-Methylthiofentanyl .......................................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (DOB) ................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ............................................................................................................................
4-Fluoro-N-methylcathinone (4-FMC) ............................................................................................................................................
4-Methoxyamphetamine ................................................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (DOM) ................................................................................................................................
4-Methylaminorex ..........................................................................................................................................................................
4-Methyl-N-ethylcathinone (4-MEC) ..............................................................................................................................................
4-Methyl-N-methylcathinone (mephedrone) ..................................................................................................................................
4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) .........................................................................................................................
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ...................................................................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) .....................
5-Methoxy-3,4-methylenedioxyamphetamine ................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine ............................................................................................................................................
5-Methoxy-N,N-dimethyltryptamine ...............................................................................................................................................
Acetyl-alpha-methylfentanyl ...........................................................................................................................................................
Acetyldihydrocodeine .....................................................................................................................................................................
Acetylmethadol ..............................................................................................................................................................................
Allylprodine ....................................................................................................................................................................................
Alphacetylmethadol ........................................................................................................................................................................
alpha-Ethyltryptamine ....................................................................................................................................................................
Alphameprodine .............................................................................................................................................................................
Alphamethadol ...............................................................................................................................................................................
alpha-Methylfentanyl ......................................................................................................................................................................
alpha-Methylthiofentanyl ................................................................................................................................................................
alpha-Methyltryptamine (AMT) ......................................................................................................................................................
alpha-Pyrrolidinobutiophenone (a-PBP) ........................................................................................................................................
alpha-Pyrrolidinopentiophenone (a-PVP) ......................................................................................................................................
Aminorex ........................................................................................................................................................................................
Benzylmorphine .............................................................................................................................................................................
Betacetylmethadol .........................................................................................................................................................................
beta-Hydroxy-3-methylfentanyl ......................................................................................................................................................
beta-Hydroxyfentanyl .....................................................................................................................................................................
Betameprodine ...............................................................................................................................................................................
Betamethadol .................................................................................................................................................................................
Betaprodine ....................................................................................................................................................................................
Bufotenine ......................................................................................................................................................................................
Cathinone .......................................................................................................................................................................................
Codeine methylbromide .................................................................................................................................................................
Codeine-N-oxide ............................................................................................................................................................................
Desomorphine ................................................................................................................................................................................
Diethyltryptamine ...........................................................................................................................................................................
Difenoxin ........................................................................................................................................................................................
Dihydromorphine ............................................................................................................................................................................
Dimethyltryptamine ........................................................................................................................................................................
Dipipanone .....................................................................................................................................................................................
Fenethylline ....................................................................................................................................................................................
gamma-Hydroxybutyric acid ..........................................................................................................................................................
Heroin ............................................................................................................................................................................................
Hydromorphinol ..............................................................................................................................................................................
Hydroxypethidine ...........................................................................................................................................................................
Ibogaine .........................................................................................................................................................................................
Lysergic acid diethylamide (LSD) ..................................................................................................................................................
VerDate Sep<11>2014
20:59 Jul 16, 2015
Jkt 235001
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
E:\FR\FM\17JYN1.SGM
17JYN1
25
30
25
30
15
25
25
25
25
30
30
25
55
50
40
50
35
25
2
2
25
25
25
150
25
25
25
45
25
68
53
25
25
25
2
2
2
2
2
25
2
2
2
2
25
25
25
25
2
2
2
2
2
4
2
3
70
5
305
25
25
11,000
3,000,000
35
5
5
70,250,000
50
2
2
5
40
Federal Register / Vol. 80, No. 137 / Friday, July 17, 2015 / Notices
42543
Proposed 2016
quotas
(g)
Basic class
Marihuana ......................................................................................................................................................................................
Mescaline .......................................................................................................................................................................................
Methaqualone ................................................................................................................................................................................
Methcathinone ...............................................................................................................................................................................
Methyldesorphine ...........................................................................................................................................................................
Methyldihydromorphine ..................................................................................................................................................................
Morphine methylbromide ...............................................................................................................................................................
Morphine methylsulfonate ..............................................................................................................................................................
Morphine-N-oxide ..........................................................................................................................................................................
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) ..................................................................................................
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA) ...............................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) ....................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) ..............................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) ........................................................
N,N-Dimethylamphetamine ............................................................................................................................................................
Naphthylpyrovalerone (naphyrone) ...............................................................................................................................................
N-Benzylpiperazine ........................................................................................................................................................................
N-Ethyl-1-phenylcyclohexylamine ..................................................................................................................................................
N-Ethylamphetamine .....................................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ................................................................................................................................
Noracymethadol .............................................................................................................................................................................
Norlevorphanol ...............................................................................................................................................................................
Normethadone ...............................................................................................................................................................................
Normorphine ..................................................................................................................................................................................
Para-fluorofentanyl .........................................................................................................................................................................
Parahexyl .......................................................................................................................................................................................
Phenomorphan ..............................................................................................................................................................................
Pholcodine .....................................................................................................................................................................................
Psilocybin .......................................................................................................................................................................................
Psilocyn ..........................................................................................................................................................................................
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22) ..................................................................
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; QUPIC) ..................................................................................................
Tetrahydrocannabinols ..................................................................................................................................................................
Thiofentanyl ...................................................................................................................................................................................
Tilidine ............................................................................................................................................................................................
Trimeperidine .................................................................................................................................................................................
200,000
25
10
25
5
2
5
5
350
25
25
25
15
15
25
25
25
5
24
24
2
52
2
40
5
5
2
5
30
50
25
25
511,250
2
25
2
srobinson on DSK5SPTVN1PROD with NOTICES
Schedule II
1-Phenylcyclohexylamine ..............................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile ..............................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) ...................................................................................................................................
Alfentanil ........................................................................................................................................................................................
Alphaprodine ..................................................................................................................................................................................
Amobarbital ....................................................................................................................................................................................
Amphetamine (for conversion) ......................................................................................................................................................
Amphetamine (for sale) .................................................................................................................................................................
Carfentanil ......................................................................................................................................................................................
Cocaine ..........................................................................................................................................................................................
Codeine (for conversion) ...............................................................................................................................................................
Codeine (for sale) ..........................................................................................................................................................................
Dextropropoxyphene ......................................................................................................................................................................
Dihydrocodeine ..............................................................................................................................................................................
Diphenoxylate (for conversion) ......................................................................................................................................................
Diphenoxylate (for sale) .................................................................................................................................................................
Ecgonine ........................................................................................................................................................................................
Ethylmorphine ................................................................................................................................................................................
Fentanyl .........................................................................................................................................................................................
Glutethimide ...................................................................................................................................................................................
Hydrocodone (for conversion) .......................................................................................................................................................
Hydrocodone (for sale) ..................................................................................................................................................................
Hydromorphone .............................................................................................................................................................................
Isomethadone ................................................................................................................................................................................
Levo-alphacetylmethadol (LAAM) ..................................................................................................................................................
Levomethorphan ............................................................................................................................................................................
Levorphanol ...................................................................................................................................................................................
Lisdexamfetamine ..........................................................................................................................................................................
Meperidine .....................................................................................................................................................................................
Meperidine Intermediate-A ............................................................................................................................................................
Meperidine Intermediate-B ............................................................................................................................................................
Meperidine Intermediate-C ............................................................................................................................................................
Metazocine .....................................................................................................................................................................................
VerDate Sep<11>2014
20:59 Jul 16, 2015
Jkt 235001
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
E:\FR\FM\17JYN1.SGM
17JYN1
5
5
2,950,000
17,750
3
25,125
15,000,000
37,500,000
19
200,000
50,000,000
63,900,000
45
226,375
31,250
1,337,500
125,000
3
2,300,000
3
235,000
88,500,000
7,000,000
5
4
30
7,125
29,750,000
5,450,000
6
11
6
19
42544
Federal Register / Vol. 80, No. 137 / Friday, July 17, 2015 / Notices
Proposed 2016
quotas
(g)
Basic class
Methadone (for sale) .....................................................................................................................................................................
Methadone Intermediate ................................................................................................................................................................
Methamphetamine .........................................................................................................................................................................
31,875,000
34,375,000
2,061,375
[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 750,000 grams for methamphetamine mostly for
conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)]
Methylphenidate .............................................................................................................................................................................
Morphine (for conversion) ..............................................................................................................................................................
Morphine (for sale) ........................................................................................................................................................................
Nabilone .........................................................................................................................................................................................
Noroxymorphone (for conversion) .................................................................................................................................................
Noroxymorphone (for sale) ............................................................................................................................................................
Opium (powder) .............................................................................................................................................................................
Opium (tincture) .............................................................................................................................................................................
Oripavine ........................................................................................................................................................................................
Oxycodone (for conversion) ..........................................................................................................................................................
Oxycodone (for sale) .....................................................................................................................................................................
Oxymorphone (for conversion) ......................................................................................................................................................
Oxymorphone (for sale) .................................................................................................................................................................
Pentobarbital ..................................................................................................................................................................................
Phenazocine ..................................................................................................................................................................................
Phencyclidine .................................................................................................................................................................................
Phenmetrazine ...............................................................................................................................................................................
Phenylacetone ...............................................................................................................................................................................
Racemethorphan ...........................................................................................................................................................................
Remifentanil ...................................................................................................................................................................................
Secobarbital ...................................................................................................................................................................................
Sufentanil .......................................................................................................................................................................................
Tapentadol .....................................................................................................................................................................................
Thebaine ........................................................................................................................................................................................
87,500,000
91,250,000
62,500,000
18,750
17,500,000
1,475,000
112,500
687,500
30,000,000
6,250,000
139,150,000
29,000,000
7,750,000
38,125,000
6
50
3
50
3
3,750
215,003
6,255
25,500,000
125,000,000
List I Chemicals
Ephedrine (for conversion) ............................................................................................................................................................
Ephedrine (for sale) .......................................................................................................................................................................
Phenylpropanolamine (for conversion) ..........................................................................................................................................
Phenylpropanolamine (for sale) .....................................................................................................................................................
Pseudoephedrine (for conversion) ................................................................................................................................................
Pseudoephedrine (for sale) ...........................................................................................................................................................
The Administrator further proposes
that the aggregate production quotas for
all other basic classes of schedule I and
II controlled substances included in 21
CFR 1308.11 and 1308.12 remain at
zero. In accordance with 21 CFR
1303.13 and 21 CFR 1315.13, upon
consideration of the relevant factors, the
Administrator may adjust the 2016
aggregate production quotas and
assessment of annual needs as
necessary.
Dated: July 13, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015–17561 Filed 7–16–15; 8:45 am]
srobinson on DSK5SPTVN1PROD with NOTICES
BILLING CODE P
VerDate Sep<11>2014
20:59 Jul 16, 2015
Jkt 235001
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration: Meda Pharmaceuticals,
Inc.
ACTION:
Notice of registration.
Meda Pharmaceuticals, Inc.
applied to be registered as an importer
of a certain basic class of controlled
substance. The Drug Enforcement
Administration (DEA) grants Meda
Pharmaceuticals, Inc. registration as an
importer of this controlled substance.
SUPPLEMENTARY INFORMATION: By notice
dated March 20, 2015, and published in
the Federal Register on March 27, 2015,
80 FR 16426, Meda Pharmaceuticals,
Inc., 705 Eldorado Street, Decatur,
Illinois 62523 applied to be registered as
an importer of a certain basic class of
controlled substance. No comments or
SUMMARY:
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
100,000
4,000,000
22,400,000
8,500,000
7,000
224,500,000
objections were submitted for this
notice.
The DEA has considered the factors in
21 U.S.C. 823, 952(a) and 958(a) and
determined that the registration of Meda
Pharmaceuticals, Inc. to import the
basic class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. The
DEA investigated the company’s
maintenance of effective controls
against diversion by inspecting and
testing the company’s physical security
systems, verifying the company’s
compliance with state and local laws,
and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above-named
company is granted registration as an
importer of nabilone (7379) a basic class
of controlled substance listed in
schedule II.
E:\FR\FM\17JYN1.SGM
17JYN1
Agencies
[Federal Register Volume 80, Number 137 (Friday, July 17, 2015)]
[Notices]
[Pages 42540-42544]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-17561]
[[Page 42540]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-420N]
Proposed Aggregate Production Quotas for Schedule I and II
Controlled Substances and Assessment of Annual Needs for the List I
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Notice with request for comments.
-----------------------------------------------------------------------
SUMMARY: The Drug Enforcement Administration proposes to establish the
2016 aggregate production quotas for controlled substances in schedules
I and II of the Controlled Substances Act and assessment of annual
needs for the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine.
DATES: Interested persons may file written comments on or objections to
this notice in accordance with 21 CFR 1303.11(c) and 1315.11(d).
Electronic comments must be submitted, and written comments must be
postmarked, on or before August 17, 2015. Commenters should be aware
that the electronic Federal Docket Management System will not accept
comments after 11:59 p.m. Eastern Time on the last day of the comment
period.
The Administrator may hold a public hearing on one or more issues
raised by the comments received in response to this notice. In the
event the Administrator decides in his sole discretion to hold such a
hearing, the Administrator will publish a notice of any such hearing in
the Federal Register. After consideration of any comments and after a
hearing, if one is held, the Administrator will publish in the Federal
Register a final order establishing the 2016 aggregate production
quotas for schedule I and II controlled substances, and an assessment
of annual needs for the list I chemicals ephedrine, pseudoephedrine,
and phenylpropanolamine.
ADDRESSES: To ensure proper handling of comments, please reference
``Docket No. DEA-420N'' on all correspondence, including any
attachments. The Drug Enforcement Administration encourages that all
comments be submitted electronically through the Federal eRulemaking
Portal which provides the ability to type short comments directly into
the comment field on the Web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the online
instructions at that site for submitting comments. Upon completion of
your submission you will receive a Comment Tracking Number for your
comment. Please be aware that submitted comments are not
instantaneously available for public view on Regulations.gov. If you
have received a Comment Tracking Number, your comment has been
successfully submitted and there is no need to resubmit the same
comment. Paper comments that duplicate electronic submissions are not
necessary and are discouraged. Should you wish to mail a paper comment
in lieu of an electronic comment, it should be sent via regular or
express mail to: Drug Enforcement Administration, Attention: DEA
Federal Register Representative/ODL, 8701 Morrissette Drive,
Springfield, Virginia 22152.
FOR FURTHER INFORMATION CONTACT: John R. Scherbenske, Office of
Diversion Control, Drug Enforcement Administration; Mailing Address:
8701 Morrissette Drive, Springfield, Virginia 22152, Telephone: (202)
598-6812.
SUPPLEMENTARY INFORMATION:
Posting of Public Comments
Please note that all comments received in response to this docket
are considered part of the public record. They will, unless reasonable
cause is given, be made available for public inspection online at
https://www.regulations.gov. Such information includes personal
identifying information (such as your name, address, etc.) voluntarily
submitted by the commenter. The Freedom of Information Act applies to
all comments received. If you want to submit personal identifying
information (such as your name, address, etc.) as part of your comment,
but do not want it to be posted online or made available in the public
docket, you must include the phrase ``PERSONAL IDENTIFYING
INFORMATION'' in the first paragraph of your comment. You must also
place all the personal identifying information you do not want publicly
available in the first paragraph of your comment and identify what
information you want redacted.
If you want to submit confidential business information as part of
your comment, but do not want it to be made publicly available, you
must include the phrase ``CONFIDENTIAL BUSINESS INFORMATION'' in the
first paragraph of your comment. You must also prominently identify
confidential business information to be redacted within the comment.
Comments containing personal identifying information or
confidential business information identified and located as directed
above will generally be made available in redacted form. If a comment
contains so much personal identifying information or confidential
business information that it cannot be effectively redacted, all or
part of that comment may not be made publicly available. Comments
posted to https://www.regulations.gov may include any personal
identifying information (such as name, address, and phone number)
included in the text of your electronic submission that is not
identified as directed above as personal.
An electronic copy of this document is available at https://www.regulations.gov for easy reference.
Legal Authority
The Drug Enforcement Administration (DEA) implements and enforces
titles II and III of the Comprehensive Drug Abuse Prevention and
Control Act of 1970, as amended. 21 U.S.C. 801-971. Titles II and III
are referred to as the ``Controlled Substances Act'' and the
``Controlled Substances Import and Export Act,'' respectively, and are
collectively referred to as the ``Controlled Substances Act'' or the
``CSA'' for the purpose of this action. The DEA publishes the
implementing regulations for these statutes in title 21 of the Code of
Federal Regulations (CFR), chapter II. The CSA and its implementing
regulations are designed to prevent, detect, and eliminate the
diversion of controlled substances and listed chemicals into the
illicit market while ensuring an adequate supply is available for the
legitimate medical, scientific, research, and industrial needs of the
United States. Controlled substances have the potential for abuse and
dependence and are controlled to protect the public health and safety.
Section 306 of the CSA (21 U.S.C. 826) requires the Attorney
General to establish aggregate production quotas for each basic class
of controlled substance listed in schedules I and II and to establish
the assessment of annual needs for the list I chemicals ephedrine,
pseudoephedrine, and phenylpropanolamine. The Attorney General has
delegated this function to the Administrator of the DEA pursuant to 28
CFR 0.100.
Analysis for Proposed 2016 Aggregate Production Quotas and Assessment
of Annual Needs
The proposed year 2016 aggregate production quotas and assessment
of annual needs represent those quantities
[[Page 42541]]
of schedule I and II controlled substances, and the list I chemicals
ephedrine, pseudoephedrine, and phenylpropanolamine, to be manufactured
in the United States in 2016 to provide for the estimated medical,
scientific, research, and industrial needs of the United States, lawful
export requirements, and the establishment and maintenance of reserve
stocks. These proposals include estimated imports of ephedrine,
pseudoephedrine, and phenylpropanolamine but do not include estimated
imports of controlled substances for use in industrial processes.
In determining the proposed 2016 aggregate production quotas and
assessment of annual needs, the Administrator has taken into account
the criteria that is required to be considered in accordance with 21
U.S.C. 826(a), 21 CFR 1303.11 (aggregate production quotas for
controlled substances), and 21 CFR 1315.11 (assessment of annual needs
for ephedrine, pseudoephedrine, and phenylpropanolamine). The
Administrator estimates the aggregate production quotas and assessment
of annual needs for 2016 by considering the following factors: (1)
Total net disposal of each class or chemical by all manufacturers and
chemical importers during the current and two preceding years; (2)
trends in the national rate of net disposal of the class or chemical;
(3) total actual (or estimated) inventories of the class or chemical
and of all substances manufactured from the class or chemical, and
trends in inventory accumulation; (4) projected demand for each class
or chemical as indicated by procurement and chemical import quotas
requested in accordance with 21 CFR 1303.12, 1315.32, and 1315.34; and
(5) other factors affecting the medical, scientific, research, and
industrial needs of the United States, lawful export requirements, and
reserve stocks, as the Administrator finds relevant.
Other factors the Administrator considered in calculating the
aggregate production quotas, but not the assessment of annual needs,
include product development requirements of both bulk and finished
dosage form manufacturers, and other pertinent information. In
determining the proposed 2016 assessment of annual needs, the DEA used
the calculation methodology previously described in the 2010 and 2011
assessments of annual needs (74 FR 60294, Nov. 20, 2009, and 75 FR
79407, Dec. 20, 2010, respectively).
The Administrator also specifically considered that inventory
allowances granted to individual manufacturers may not always result in
the availability of sufficient quantities to maintain an adequate
reserve stock pursuant to 21 U.S.C. 826(a), as intended. See 21 CFR
1303.24. This would be of concern if a natural disaster or other
unforeseen event resulted in substantial disruption to the amount of
controlled substances available to provide for legitimate public need.
As such, the Administrator proposes to include in all schedule II
aggregate production quotas, and certain schedule I aggregate
production quotas (difenoxin, gamma-hydroxybutyric acid, and
tetrahydrocannabinols), an additional 25% of the estimated medical,
scientific, and research needs as part of the amount necessary to
ensure the establishment and maintenance of reserve stocks. The
proposed aggregate production quotas reflect these included amounts.
This action will not affect the ability of manufacturers to maintain
inventory allowances as specified by regulation. The Administrator
expects that maintaining this reserve in certain established aggregate
production quotas will mitigate adverse public effects if an unforeseen
event results in substantial disruption to the amount of controlled
substances available to provide for legitimate public need, as
determined by the Administrator. The Administrator does not anticipate
utilizing the reserve in the absence of these circumstances.
The Administrator, therefore, proposes to establish the 2016
aggregate production quotas for the following basic classes of schedule
I and II controlled substances and assessment of annual needs for the
list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine,
expressed in grams of anhydrous acid or base, as follows:
------------------------------------------------------------------------
Proposed 2016
Basic class quotas (g)
------------------------------------------------------------------------
Schedule I
------------------------------------------------------------------------
(1-Pentyl-1H-indol-3-yl)(2,2,3,3- 25
tetramethylcyclopropyl)methanone (UR-144)...........
[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3- 25
tetramethylcyclopropyl)methanone (XLR11)............
[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1- 15
yl)methanone (THJ-2201).............................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one 25
(butylone)..........................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one 25
(pentylone).........................................
1-(1-Phenylcyclohexyl)pyrrolidine.................... 10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201).... 45
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)... 45
1-[1-(2-Thienyl)cyclohexyl]piperidine................ 15
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH- 45
200)................................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073).............. 45
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR- 45
18 and RCS-8).......................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019).............. 45
1-Methyl-4-phenyl-4-propionoxypiperidine............. 2
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)... 45
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).... 45
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)... 45
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398).... 45
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122).... 45
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) 45
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081).. 45
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P).. 30
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)..... 30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D).... 30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N).... 30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)............. 30
[[Page 42542]]
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2- 25
methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe;
25B; Cimbi-36)......................................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C).... 30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2- 25
methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe;
25C; Cimbi-82)......................................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)...... 30
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2- 15
methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe;
25I; Cimbi-5).......................................
2-(Methylamino)-1-phenylpentan-1-one (pentedrone).... 25
2,5-Dimethoxy-4-ethylamphetamine (DOET).............. 25
2,5-Dimethoxy-4-n-propylthiophenethylamine........... 25
2,5-Dimethoxyamphetamine............................. 25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T- 30
2)..................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine 30
(2C-T-4)............................................
3,4,5-Trimethoxyamphetamine.......................... 25
3,4-Methylenedioxyamphetamine (MDA).................. 55
3,4-Methylenedioxymethamphetamine (MDMA)............. 50
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)......... 40
3,4-Methylenedioxy-N-methylcathinone (methylone)..... 50
3,4-Methylenedioxypyrovalerone (MDPV)................ 35
3-Fluoro-N-methylcathinone (3-FMC)................... 25
3-Methylfentanyl..................................... 2
3-Methylthiofentanyl................................. 2
4-Bromo-2,5-dimethoxyamphetamine (DOB)............... 25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)........... 25
4-Fluoro-N-methylcathinone (4-FMC)................... 25
4-Methoxyamphetamine................................. 150
4-Methyl-2,5-dimethoxyamphetamine (DOM).............. 25
4-Methylaminorex..................................... 25
4-Methyl-N-ethylcathinone (4-MEC).................... 25
4-Methyl-N-methylcathinone (mephedrone).............. 45
4-Methyl-[alpha]-pyrrolidinopropiophenone (4-MePPP).. 25
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3- 68
hydroxycyclohexyl]-phenol...........................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- 53
phenol (cannabicyclohexanol or CP-47,497 C8-homolog)
5-Methoxy-3,4-methylenedioxyamphetamine.............. 25
5-Methoxy-N,N-diisopropyltryptamine.................. 25
5-Methoxy-N,N-dimethyltryptamine..................... 25
Acetyl-alpha-methylfentanyl.......................... 2
Acetyldihydrocodeine................................. 2
Acetylmethadol....................................... 2
Allylprodine......................................... 2
Alphacetylmethadol................................... 2
alpha-Ethyltryptamine................................ 25
Alphameprodine....................................... 2
Alphamethadol........................................ 2
alpha-Methylfentanyl................................. 2
alpha-Methylthiofentanyl............................. 2
alpha-Methyltryptamine (AMT)......................... 25
alpha-Pyrrolidinobutiophenone ([alpha]-PBP).......... 25
alpha-Pyrrolidinopentiophenone ([alpha]-PVP)......... 25
Aminorex............................................. 25
Benzylmorphine....................................... 2
Betacetylmethadol.................................... 2
beta-Hydroxy-3-methylfentanyl........................ 2
beta-Hydroxyfentanyl................................. 2
Betameprodine........................................ 2
Betamethadol......................................... 4
Betaprodine.......................................... 2
Bufotenine........................................... 3
Cathinone............................................ 70
Codeine methylbromide................................ 5
Codeine-N-oxide...................................... 305
Desomorphine......................................... 25
Diethyltryptamine.................................... 25
Difenoxin............................................ 11,000
Dihydromorphine...................................... 3,000,000
Dimethyltryptamine................................... 35
Dipipanone........................................... 5
Fenethylline......................................... 5
gamma-Hydroxybutyric acid............................ 70,250,000
Heroin............................................... 50
Hydromorphinol....................................... 2
Hydroxypethidine..................................... 2
Ibogaine............................................. 5
Lysergic acid diethylamide (LSD)..................... 40
[[Page 42543]]
Marihuana............................................ 200,000
Mescaline............................................ 25
Methaqualone......................................... 10
Methcathinone........................................ 25
Methyldesorphine..................................... 5
Methyldihydromorphine................................ 2
Morphine methylbromide............................... 5
Morphine methylsulfonate............................. 5
Morphine-N-oxide..................................... 350
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide 25
(AKB48).............................................
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H- 25
indazole-3-carboxamide (ADB-PINACA).................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4- 25
fluorobenzyl)-1H-indazole-3-carboxamide (AB-
FUBINACA)...........................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1- 15
(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-
CHMINACA)...........................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H- 15
indazole-3-carboxamide (AB-PINACA)..................
N,N-Dimethylamphetamine.............................. 25
Naphthylpyrovalerone (naphyrone)..................... 25
N-Benzylpiperazine................................... 25
N-Ethyl-1-phenylcyclohexylamine...................... 5
N-Ethylamphetamine................................... 24
N-Hydroxy-3,4-methylenedioxyamphetamine.............. 24
Noracymethadol....................................... 2
Norlevorphanol....................................... 52
Normethadone......................................... 2
Normorphine.......................................... 40
Para-fluorofentanyl.................................. 5
Parahexyl............................................ 5
Phenomorphan......................................... 2
Pholcodine........................................... 5
Psilocybin........................................... 30
Psilocyn............................................. 50
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3- 25
carboxylate (5-fluoro-PB-22; 5F-PB-22)..............
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB- 25
22; QUPIC)..........................................
Tetrahydrocannabinols................................ 511,250
Thiofentanyl......................................... 2
Tilidine............................................. 25
Trimeperidine........................................ 2
------------------------------------------------------------------------
Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine.............................. 5
1-Piperidinocyclohexanecarbonitrile.................. 5
4-Anilino-N-phenethyl-4-piperidine (ANPP)............ 2,950,000
Alfentanil........................................... 17,750
Alphaprodine......................................... 3
Amobarbital.......................................... 25,125
Amphetamine (for conversion)......................... 15,000,000
Amphetamine (for sale)............................... 37,500,000
Carfentanil.......................................... 19
Cocaine.............................................. 200,000
Codeine (for conversion)............................. 50,000,000
Codeine (for sale)................................... 63,900,000
Dextropropoxyphene................................... 45
Dihydrocodeine....................................... 226,375
Diphenoxylate (for conversion)....................... 31,250
Diphenoxylate (for sale)............................. 1,337,500
Ecgonine............................................. 125,000
Ethylmorphine........................................ 3
Fentanyl............................................. 2,300,000
Glutethimide......................................... 3
Hydrocodone (for conversion)......................... 235,000
Hydrocodone (for sale)............................... 88,500,000
Hydromorphone........................................ 7,000,000
Isomethadone......................................... 5
Levo-alphacetylmethadol (LAAM)....................... 4
Levomethorphan....................................... 30
Levorphanol.......................................... 7,125
Lisdexamfetamine..................................... 29,750,000
Meperidine........................................... 5,450,000
Meperidine Intermediate-A............................ 6
Meperidine Intermediate-B............................ 11
Meperidine Intermediate-C............................ 6
Metazocine........................................... 19
[[Page 42544]]
Methadone (for sale)................................. 31,875,000
Methadone Intermediate............................... 34,375,000
Methamphetamine...................................... 2,061,375
------------------------------------------------------------------------
[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled,
non-prescription product; 750,000 grams for methamphetamine mostly for
conversion to a schedule III product; and 61,375 grams for
methamphetamine (for sale)]
------------------------------------------------------------------------
Methylphenidate...................................... 87,500,000
Morphine (for conversion)............................ 91,250,000
Morphine (for sale).................................. 62,500,000
Nabilone............................................. 18,750
Noroxymorphone (for conversion)...................... 17,500,000
Noroxymorphone (for sale)............................ 1,475,000
Opium (powder)....................................... 112,500
Opium (tincture)..................................... 687,500
Oripavine............................................ 30,000,000
Oxycodone (for conversion)........................... 6,250,000
Oxycodone (for sale)................................. 139,150,000
Oxymorphone (for conversion)......................... 29,000,000
Oxymorphone (for sale)............................... 7,750,000
Pentobarbital........................................ 38,125,000
Phenazocine.......................................... 6
Phencyclidine........................................ 50
Phenmetrazine........................................ 3
Phenylacetone........................................ 50
Racemethorphan....................................... 3
Remifentanil......................................... 3,750
Secobarbital......................................... 215,003
Sufentanil........................................... 6,255
Tapentadol........................................... 25,500,000
Thebaine............................................. 125,000,000
------------------------------------------------------------------------
List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion)........................... 100,000
Ephedrine (for sale)................................. 4,000,000
Phenylpropanolamine (for conversion)................. 22,400,000
Phenylpropanolamine (for sale)....................... 8,500,000
Pseudoephedrine (for conversion)..................... 7,000
Pseudoephedrine (for sale)........................... 224,500,000
------------------------------------------------------------------------
The Administrator further proposes that the aggregate production
quotas for all other basic classes of schedule I and II controlled
substances included in 21 CFR 1308.11 and 1308.12 remain at zero. In
accordance with 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration
of the relevant factors, the Administrator may adjust the 2016
aggregate production quotas and assessment of annual needs as
necessary.
Dated: July 13, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015-17561 Filed 7-16-15; 8:45 am]
BILLING CODE P